Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
3 days ago
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

Organ damage, anti-dsDNA antibodies predict belimumab efficacy in lupus

11 Jul 2019

Belimumab treatment for systemic lupus erythematosus (SLE) may induce low disease activity (LDA) and clinical remission in patients with limited or no organ damage, as well as with positive antidouble stranded DNA (anti-dsDNA) titres, according to a study.

The study used data from the BLISS-52 and BLISS-76 trials and included 563 SLE patients (mean age, 37.9 years; 95.7 percent female) who received belimumab 10 mg/kg. Researchers used logistic regression to evaluate the performance of baseline factors in predicting achievement of LDA (assessed using Lupus Low Disease Activity State [LLDAS]) or clinical remission (defined as SLE Disease Activity Index 2000 score of 0) at week 52 from treatment initiation.

Organ damage (assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index [SDI]) reduced the likelihood of attaining LDA (SDI >0: odds ratio (OR), 0.44, 95 percent CI, 0.22–0.90; p=0.024) and the primary LLDAS condition (ie, SLEDAI-2K 4 with no renal activity, pleurisy, pericarditis or fever; SDI >1: OR, 0.46, 0.27–0.77; p=0.004). The association between organ damage and failure to achieve the primary LLDAS condition was attributed mainly to cognitive impairment/psychosis prior to belimumab initiation.

Baseline SDI scores >1 also predicted failure to attain clinical remission (OR, 0.53, 0.30–0.94; p=0.030), with cutaneous damage largely driving this association.

On the other hand, anti-dsDNA positivity increased the probability of attaining clinical remission, along with reduced prednisone intake (7.5 mg/day), by about 80 percent (OR, 1.82, 1.08–3.06; p=0.025). However, cardiovascular damage reduced the probability of such an outcome (OR, 0.13, 0.02–0.97; p=0.047).

The associations observed were independent of age, SLE disease duration or SLE activity grade, the researchers noted, adding that the data overall have important clinical implications with respect to optimization of the use of belimumab.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
3 days ago
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.